Market Trends of Extra Corporeal Membrane Oxygenation (ECMO) System Industry
Respiratory Applications is Expected to Witness Significant Growth Over the Forecast Period
The respiratory segment is expected to witness significant growth in the extracorporeal membrane oxygenation devices market over the forecast period owing to factors such as the increasing burden of respiratory diseases among the population and growing company activities.
The rising prevalence and incidence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonia, and lung cancer, among the population is the key factor driving the demand for respiratory support equipment such as ECMO machines. For instance, according to an article published in ERS Journal in August 2022, about 645.6 million people (454.4 million men and 191.2 million women) were expected to experience COPD by 2050, representing a 36% relative increase in global prevalence compared to the previous year. Similarly, according to the 2022 statistics published by the National Cancer Registry Programme, about 1,03,371 new lung cancer cases were reported in India in 2022, compared to 98,278 cases in the last year.
Furthermore, as per the study published in the ASAIO Journal in April 2022, it was observed that 83 adult patients had dynamic or hybrid ECMO configurations. Their primary diagnoses included cardiogenic shock (33.7%), cardiac arrest (6.0%), acute respiratory failure (39.8%), septic shock (9.6%), multiple trauma (3.6%), pulmonary hypertension (3.6%), and others (3.6%). The study concluded that dynamic or hybrid configurations for extracorporeal membrane oxygenation (ECMO) were needed when patient physiology or clinical conditions changed. Thus, the increasing adoption of membrane oxygenators during physiological or clinical condition changes is expected to boost the growth of the market studied over the forecast period.
Moreover, the rising product launches are also contributing to segment growth. For instance, in November 2022, LivaNova PLC received the US FDA's approval for its extracorporeal membrane oxygenation (ECMO). LifeSPARC is a next-generation advanced circulatory support (ACS) pump and controller system for cardiopulmonary bypass.
Therefore, the segment is expected to grow over the forecast period due to the factors above, such as the high burden of respiratory diseases, the growing adoption of extracorporeal life support systems, and increasing product launches.
North America is Expected to Record Significant Market Share Over the Forecast Period
North America is expected to hold a significant market share over the forecast period owing to its increasing prevalence of cardiovascular and respiratory diseases, advancements in ECMO technology, and increased adoption of advanced life support equipment.
The increasing burden of cardiovascular diseases and their associated risk factors, such as high blood pressure, obesity, type-2 diabetes, and poor dietary habits, increase the population's risk of developing chronic heart diseases, propelling market growth. For instance, as per 2022 statistics published by IDF, people living with diabetes in Canada are projected to reach 3.2 million by 2030 and 3.4 million by 2045. Therefore, high blood sugar caused by diabetes can damage the nerves that control the heart and blood vessels, leading to cardiovascular diseases like coronary artery disease and stroke, narrowing the arteries and necessitating coronary artery bypass procedures. These procedures call for life support systems, which are projected to enhance demand for ECMO machines and spur market expansion.
In addition, the increasing geriatric population is more prone to developing cardiopulmonary diseases, which may lead to surgeries. It increases the demand for ECMO systems and heart lung machines, which is expected to fuel market growth over the forecast period. For instance, as per 2022 statistics published by UNPF, about 17% and 19% of the US and Canadian population was 65 years and above in 2022.
Furthermore, as per 2022 statistics published by WHO, West Virginia recorded the highest smoking rate at 23.8%, followed by Kentucky at 23.6%, Louisiana at 21.9%, and Ohio at 20.8% in 2022. Thus, the high number of smokers in the region are at high risk of developing various lung diseases such as COPD. This, in turn, raises the demand for respiratory support equipment, propelling market growth.
Moreover, the growing number of new product launches and approvals is also contributing to the region's market growth. For instance, in July 2022, Inspira Technologies, an ECMO company, revealed its Liby System, an advanced form of extracorporeal life support ECMO device used to treat patients with life-threatening heart and lung failure. The system was expected to be submitted to the US Food and Drug Administration (FDA) for approval during the first half of 2023.
Therefore, the market studied is expected to grow over the forecast period due to the above factors, such as the high burden of cardiovascular and respiratory diseases and increasing product launches.
